Previous 10 | Next 10 |
BARDOXOLONE ACHIEVED THE YEAR 2 PRIMARY AND KEY SECONDARY ENDPOINT S WITH STATISTICALLY SIGNIFICANT IMPROVEMENT S IN EGFR AS COMPARED TO PLACEBO AT WEEK 100 AND WEEK 104 ...
REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME REPORTED LONG TERM EFFICACY DATA FROM EAGLE (OPEN-LABEL EXTENSION ) STUDY ...
[[ALE]], [[BCOR]], [[BHVN]], [[BIP]], [[BKI]], [[BTU]], [[CARS]], [[CGC]], [[CNNE]], [[EBIX]], [[GOGO]], [[HL]], [[HWM]], [[ICPT]], [[MCD]], [[PLUG]], [[RDNT]], [[RETA]], [[TGNA]]For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings bef...
Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q3 earnings results on Monday, November 9th, before market open.The consensus EPS Estimate is -$1.85 (-40.2% Y/Y) and the consensus Revenue Estimate is $1.28M (-84.5% Y/Y).Over the last 2 years, RETA has beaten EPS estimates 25% of ...
PLANO, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on ...
PLANO, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (“Reata” or “the Company” or “we”) announced today the upcoming presentation of K ID NEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Diseas...
Today, we take an in-depth look at Reata Pharmaceuticals. After surging north of $250 in early February 2020, the shares have lost ~55% of their value. An August 2020 regulatory update added timing uncertainty to one of its Nrf2 targeting candidates (Bard) and FDA approval uncerta...
PLANO, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the forthcoming presentation of efficacy and safety results fr...
Reata Slips on operational updates including omaveloxolone setback Reata Pharmaceuticals Inc. ( RETA ) announced its second quarter financial numbers and provided an update for its business operations. However, the markets reacted negatively to the news, leading the company stock to plun...
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q2 2020 Earnings Call Aug 10, 2020 , 8:30 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023